Conavi Medical Awarded 2026 TAG Innovation Award

• Conavi Medical Corp. received the 2026 TAG Innovation Award from The Aebli Group on April 23, 2026.
• The award recognizes innovation and leadership in healthcare technology, specifically following the recent U.S. FDA 510(k) clearance of its next-generation hybrid intravascular imaging system (announced April 20, 2026).
• The company is entering a phase focused on U.S. commercialization for its integrated IVUS and OCT platform.
• CEO Tom Looby stated the award reflects technology strength and team dedication as they transition to commercial launch.
• Historical context shows a progression from FY2025 results (Dec 2025) showing reduced net loss but high burn, through a $12M equity closing in Jan 2026, to Q1 FY2026 results (Feb 2026) highlighting cash constraints ($1.0M cash on hand).
• The April 20 news confirmed FDA clearance enabling commercial launch expected in H2 2026.

• Incremental Validation: The TAG Award is a positive validation of the technology but does not introduce new financial data or contracts beyond what was announced with the FDA clearance three days prior.
• Cash Burn Reality: Despite regulatory success, Q1 FY2026 results showed an operating loss of $5.1M and cash on hand of only $1.0M (as of Dec 31, 2025). The Jan 2026 financing raised ~$12M, extending runway but not eliminating the need for near-term revenue generation.
• Commercialization Timeline: Commercial launch is targeted for H2 2026. The award reinforces confidence in the product but does not accelerate the timeline or guarantee immediate sales volume.
• Market Expectations: The FDA clearance was the primary material catalyst; this award serves as a confirmation event rather than a surprise driver of value.

• Company: Conavi Medical Corp., focused on intravascular imaging technology.
• Flagship Project: Novasight Hybrid™ IVUS-OCT system (next-generation).
• Technology: Integrates Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) into a single system for simultaneous vessel structure and surface detail visualization.
• Regulatory Status: First-gen system cleared in U.S., Canada, China, Japan; Next-gen received FDA 510(k) clearance April 2026.
• Clinical Validation: Peer-reviewed study in Cardiovascular Research (Feb 2026) demonstrated superior plaque characterization using hybrid deep-learning classifier versus single-modality imaging.